Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tango Therapeutics (TNGX) Non-cash Items (2020 - 2025)

Historic Non-cash Items for Tango Therapeutics (TNGX) over the last 6 years, with Q3 2025 value amounting to $14.7 million.

  • Tango Therapeutics' Non-cash Items rose 3901.67% to $14.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.7 million, marking a year-over-year increase of 3901.67%. This contributed to the annual value of $11.2 million for FY2024, which is 4206.03% up from last year.
  • Per Tango Therapeutics' latest filing, its Non-cash Items stood at $14.7 million for Q3 2025, which was up 3901.67% from $14.3 million recorded in Q2 2025.
  • Tango Therapeutics' Non-cash Items' 5-year high stood at $87.9 billion during Q3 2023, with a 5-year trough of $1.8 million in Q3 2021.
  • Moreover, its 5-year median value for Non-cash Items was $14.5 million (2025), whereas its average is $10.9 billion.
  • As far as peak fluctuations go, Tango Therapeutics' Non-cash Items skyrocketed by 26643154.82% in 2022, and later crashed by 9998.79% in 2024.
  • Over the past 5 years, Tango Therapeutics' Non-cash Items (Quarter) stood at $51.4 billion in 2021, then crashed by 52.8% to $24.3 billion in 2022, then plummeted by 99.74% to $62.6 million in 2023, then tumbled by 82.13% to $11.2 million in 2024, then soared by 31.77% to $14.7 million in 2025.
  • Its last three reported values are $14.7 million in Q3 2025, $14.3 million for Q2 2025, and $11.2 million during Q4 2024.